AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 31 min read$PGNY

Livingston Mark S. sold $7K of PGNY

Livingston Mark S. (CHIEF FINANCIAL OFFICER) sold 279 shares of Progyny, Inc. (PGNY) at $26.20 on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Livingston Mark S.
Published Jun 3, 2026, 8:54 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$PGNY
Neutral
medium confidence
Mentioned
$PGNY
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGNYNeutralLow
01

Why it matters

This disclosure provides incremental information about insider liquidity, but the article contains no new operational or financial developments for Progyny.

02

Market read

Traders may treat it as low-signal unless paired with other insider activity or fundamental catalysts.

03

What to watch

Consider whether there are concurrent insider buys/sales in recent filings and whether the sale size is unusual relative to prior Form 4 activity.

Relevance 6/10Novelty 3/10Timing: Filed June 3; transaction dated June 2

Background

SEC Form 4 reports insider transactions (officers/directors/10% owners). A 10b5-1 plan indicates sales were pre-scheduled to reduce timing-based trading concerns.

Company-level read

Ticker impact

$PGNYNeutralMedium confidence
Context

Progyny CFO Livingston Mark sold 279 shares in an open-market transaction under a pre-arranged 10b5-1 plan, disclosed via Form 4.

Expected impact

Likely minimal, with any effect more sentiment-driven than fundamental.

Evidence & confidence

The filing is a routine insider transaction with an explicit pre-arranged 10b5-1 plan; no earnings, guidance, or operational change is cited.

Market effects

Sector

No direct sector read-through; this is company-specific insider activity without new business information.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even 10b5-1 sales can coincide with management views on valuation; monitor for follow-on selling or changes in sale cadence.

Key entities

  • issuer
    Progyny, Inc.

    Company whose CFO disclosed an open-market sale of shares under a pre-arranged 10b5-1 plan.

  • insider
    Livingston Mark S.

    Chief Financial Officer who sold 279 shares on June 2, 2026.

Read at source← All news

Related articles

AUG 7
$PGNYMedAI 8/10

Why Progyny (PGNY) Shares Are Sliding Today

Progyny (PGNY) shares fell about 4.5% after the fertility benefits company issued weaker guidance. Q2 revenue rose to $350.5M (+5.3% YoY) and adjusted EPS was $0.55, both above estimates. But it projected $340M revenue for the next quarter, about 3% below consensus, and cut full-year revenue to $1.37B from $1.39B.

financialcontent.com5 min
AUG 7
$PGNYMed

Why Progyny Stock Plunged, Then Gradually Recovered Today

Progyny (PGNY) shares fell about 6% after its Q2 earnings. The company reported 5% sales growth, with adjusted EPS up 15% versus expectations. Q3 sales guidance calls for 7% to 11% growth and adjusted earnings are slightly lower sequentially. Gross margins rose 180 bps and covered members increased 7% to 7.2 million.

yahoo.com3 min
AUG 6
$PGNYMed

Progyny, Inc. (PGNY): Results of Operations and Financial Condition

Progyny, Inc. (PGNY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026.htm EX-99.1 Document Progyny, Inc. Announces Second Quarter 2026 Results Reports Record Quarterly Revenue, Gross Profit and Adjusted EBITDA Robust Selling Season Activity Continues to Reflect Strong Demand for Women's Health, Family Building Solutions V

SEC EDGAR 8-K4 min
JUL 13
$PGNYMed

Progyny (PGNY) Stock Is Up, What You Need To Know

Progyny (PGNY) shares rose 3.5% to $31.73 after KeyBanc raised its price target to $35 from $30 and kept an Overweight rating, citing expectations for a strong earnings report and higher future guidance. The article also notes other bullish analyst actions, including Truist raising its target and Canaccord upgrading to Buy.

financialcontent.com4 min
MAY 31
$PGNYMedAI 8/10

A Progyny (PGNY) Insider Sold 5,500 Shares for $137,000

Progeny (PGNY) director Kevin Gordon sold 5,500 shares for about $137,000, according to the article. The firm reported Q1 revenue of $328 million, up 1.4% YoY, with gross profit rising 10% to $83.1 million. It said client growth and retention were strong aside from a large client loss, and approved a $200 million share repurchase program.

finance.yahoo.com5 min